ArticleFrontiers in oncology2026
Case Report: Discordant diffuse large B-cell lymphoma and splenic peripheral T-cell lymphoma revealed by persistent splenomegaly and cytopenia.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discordant lymphomas involving mature B-cell and T-cell neoplasms are uncommon and may be missed when atypical clinical manifestations are attributed to a known aggressive lymphoma. We report a 71-year-old man who presented with fever, generalized lymphadenopathy, splenomegaly, splenic infarction, anemia, and thrombocytopenia. Bone marrow, flow cytometry, and tissue immunohistochemistry supported stage IVB diffuse large B-cell lymphoma (DLBCL), non-germinal-center B-cell-like subtype, with bone marrow involvement. After dose-reduced R-CHOPE chemotherapy, partial remission was achieved, but thrombocytopenia and marked splenomegaly persisted. Splenectomy, performed for suspected hypersplenism, unexpectedly showed peripheral T-cell lymphoma with loss of B-cell markers and clonal TCRG and TCRB rearrangements. Ten months after presentation, a right zygomatic-orbital soft tissue lesion was biopsied and confirmed recurrent DLBCL. The patient received R-GemOx plus zanubrutinib, intrathecal chemotherapy, and later R-ICE plus zanubrutinib; however, repeated relapse occurred, and he died 33 months after initial presentation. This case illustrates that persistent splenomegaly, cytopenia, splenic infarction, or anatomically discordant progression during lymphoma treatment should trigger repeat tissue sampling and integrated pathological reassessment. The distinct anatomical distribution, lineage-specific immunophenotypes, and splenic T-cell clonality supported the diagnosis of lineage-discordant lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.